Corporate Report

Overview

The report presents Fuji Pharma's FY2022 performance, including consolidated net sales of 35,426 million yen and profit attributable to owners of the parent of 2,696 million yen. It describes company-wide sustainability governance and 18 materiality issues. It also reports TCFD-based climate disclosure, renewable-energy initiatives and a carbon-neutrality goal for 2050.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 October 2021 – 30 September 2022
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services